We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen Gears Up to Report Q3 Earnings: Here's What to Expect
Read MoreHide Full Article
Amgen (AMGN - Free Report) will report third-quarter 2024 results on Oct. 30, after market close. In the last reported quarter, the company beat earnings expectations by 0.81%.
The Zacks Consensus Estimate for sales and earnings is pegged at $8.51 billion and $5.11 per share, respectively.
Factors to Consider for Amgen
Amgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Prolia and Blincyto among others. However, prices of most products are expected to continue to decline due to higher rebates to support expanded access.
The Zacks Consensus Estimate for Prolia, Repatha, Evenity and Blincyto sales is pegged at $1.11 billion, $523 million, $406.0 million and $274.0 million, respectively.
Our estimates for Prolia, Repatha, Evenity and Blincyto sales are pegged at $1.09 billion, $502 million, $381.9 million and $272.7 million, respectively.
In addition, higher volumes of newer drugs like Tezspire and Tavneos are expected to have contributed to top-line growth driven by new patient volume growth. Like the previous quarters, Tezspire volumes are likely to have benefited from the launch of a self-administered, pre-filled, single-use pen formulation of the drug.
Our estimates for Tezspire and Tavneos are pegged at $257.6 and $91.4 million, respectively.
Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024, recorded sales of $12 million in the second quarter. Sales are expected to be higher in the third quarter.
Enbrel sales are likely to have declined due to flat volume growth and declining prices. Otezla sales were soft in the first and second quarters. It remains to be seen if sales improved in the third quarter.
The Zacks Consensus Estimate for Otezla is $563.0 million, while our estimate is $588.0 million.
The Zacks Consensus Estimate for Enbrel is $923.0 million, while our estimate is $920.1 million.
Sales of Tepezza, Krystexxa and Uplizna, acquired from the October 2023 acquisition of Horizon, are likely to have improved the top line.
However, lower revenues from oncology biosimilars (Kanjinti and Mvasi) and legacy established products are expected to hurt the top line.
In the second half of 2024, R&D costs are expected to have increased while operating margins are expected to have been lower than the first half of 2024. Operating margin in the third quarter is expected to have been lower than the second-quarter level. In the third quarter, total adjusted costs are expected to have risen at a similar rate to the first and second quarters.
Investors will look for updates on Amgen’s important pipeline candidate, MariTide (maridebart cafraglutide), a GIPR/GLP-1 receptor for obesity, an area gaining significant popularity.
AMGN’s Earnings Surprise History
This large biotech’s performance has been strong, with earnings beating estimates in all the trailing four quarters. The company delivered a four-quarter earnings surprise of 3.47%, on average.
Amgen’s stock has risen 11% so far this year against a decrease of 3.1% for the industry.
Image Source: Zacks Investment Research
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
What Our Model Says for AMGN
Our proven model does not conclusively predict an earnings beat for Amgen this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
Earnings ESP: Amgen’s Earnings ESP is -1.07%. The Zacks Consensus Estimate is pegged at $5.11 per share, while the Most Accurate Estimate is pegged at $5.05 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Amgen has a Zacks Rank #3.
Stocks to Consider
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Pfizer’s stock is up 0.1% year to date. Pfizer exceeded earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 69.82%, on average. Pfizer is scheduled to release its third-quarter results on Oct. 29.
Regeneron (REGN - Free Report) has an Earnings ESP of +2.90% and a Zacks Rank #3.
Regeneron’s stock has risen 9.6% year to date. REGN beat earnings estimates in three of the last four quarters while missing on the remaining occasion. On average, Regeneron witnessed an earnings surprise of 6.01% in the last four quarters. REGN will report third-quarter 2024 results on Oct. 31
Biogen (BIIB - Free Report) has an Earnings ESP of +1.14% and a Zacks Rank #3.
Biogen’s stock has lost 28.2% year to date. BIIB beat earnings estimates in three of the last four quarters while missing on the remaining occasion. On average, Biogen delivered a negative earnings surprise of 10.25% in the last four quarters. BIIB will report third-quarter results on Oct. 30.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen Gears Up to Report Q3 Earnings: Here's What to Expect
Amgen (AMGN - Free Report) will report third-quarter 2024 results on Oct. 30, after market close. In the last reported quarter, the company beat earnings expectations by 0.81%.
The Zacks Consensus Estimate for sales and earnings is pegged at $8.51 billion and $5.11 per share, respectively.
Factors to Consider for Amgen
Amgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Prolia and Blincyto among others. However, prices of most products are expected to continue to decline due to higher rebates to support expanded access.
The Zacks Consensus Estimate for Prolia, Repatha, Evenity and Blincyto sales is pegged at $1.11 billion, $523 million, $406.0 million and $274.0 million, respectively.
Our estimates for Prolia, Repatha, Evenity and Blincyto sales are pegged at $1.09 billion, $502 million, $381.9 million and $272.7 million, respectively.
In addition, higher volumes of newer drugs like Tezspire and Tavneos are expected to have contributed to top-line growth driven by new patient volume growth. Like the previous quarters, Tezspire volumes are likely to have benefited from the launch of a self-administered, pre-filled, single-use pen formulation of the drug.
Our estimates for Tezspire and Tavneos are pegged at $257.6 and $91.4 million, respectively.
Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024, recorded sales of $12 million in the second quarter. Sales are expected to be higher in the third quarter.
Enbrel sales are likely to have declined due to flat volume growth and declining prices. Otezla sales were soft in the first and second quarters. It remains to be seen if sales improved in the third quarter.
The Zacks Consensus Estimate for Otezla is $563.0 million, while our estimate is $588.0 million.
The Zacks Consensus Estimate for Enbrel is $923.0 million, while our estimate is $920.1 million.
Sales of Tepezza, Krystexxa and Uplizna, acquired from the October 2023 acquisition of Horizon, are likely to have improved the top line.
However, lower revenues from oncology biosimilars (Kanjinti and Mvasi) and legacy established products are expected to hurt the top line.
In the second half of 2024, R&D costs are expected to have increased while operating margins are expected to have been lower than the first half of 2024. Operating margin in the third quarter is expected to have been lower than the second-quarter level. In the third quarter, total adjusted costs are expected to have risen at a similar rate to the first and second quarters.
Investors will look for updates on Amgen’s important pipeline candidate, MariTide (maridebart cafraglutide), a GIPR/GLP-1 receptor for obesity, an area gaining significant popularity.
AMGN’s Earnings Surprise History
This large biotech’s performance has been strong, with earnings beating estimates in all the trailing four quarters. The company delivered a four-quarter earnings surprise of 3.47%, on average.
Amgen Inc. Price and EPS Surprise
Amgen Inc. price-eps-surprise | Amgen Inc. Quote
Amgen’s stock has risen 11% so far this year against a decrease of 3.1% for the industry.
Image Source: Zacks Investment Research
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
What Our Model Says for AMGN
Our proven model does not conclusively predict an earnings beat for Amgen this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
Earnings ESP: Amgen’s Earnings ESP is -1.07%. The Zacks Consensus Estimate is pegged at $5.11 per share, while the Most Accurate Estimate is pegged at $5.05 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Amgen has a Zacks Rank #3.
Stocks to Consider
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Pfizer (PFE - Free Report) has an Earnings ESP of +2.68% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Pfizer’s stock is up 0.1% year to date. Pfizer exceeded earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 69.82%, on average. Pfizer is scheduled to release its third-quarter results on Oct. 29.
Regeneron (REGN - Free Report) has an Earnings ESP of +2.90% and a Zacks Rank #3.
Regeneron’s stock has risen 9.6% year to date. REGN beat earnings estimates in three of the last four quarters while missing on the remaining occasion. On average, Regeneron witnessed an earnings surprise of 6.01% in the last four quarters. REGN will report third-quarter 2024 results on Oct. 31
Biogen (BIIB - Free Report) has an Earnings ESP of +1.14% and a Zacks Rank #3.
Biogen’s stock has lost 28.2% year to date. BIIB beat earnings estimates in three of the last four quarters while missing on the remaining occasion. On average, Biogen delivered a negative earnings surprise of 10.25% in the last four quarters. BIIB will report third-quarter results on Oct. 30.